Journal
ONCOLOGIST
Volume 26, Issue 4, Pages E715-E718Publisher
WILEY
DOI: 10.1002/onco.13694
Keywords
-
Categories
Funding
- National Cancer Institute [P30 CA016672]
- Joan and Irwin Jacobs Fund philanthropic fund
Ask authors/readers for more resources
This study found that 9.7% of prostate cancer samples exhibited genomic abnormalities in the cyclin sensitizing pathway, with frequent alterations including CCND1 amplification and CDKN2A and B loss. Additionally, alterations in possible resistance genes RB1 and CCNE1 were detected in a smaller percentage of cases. Furthermore, cyclin sensitizing alterations were often associated with concomitant AR alterations.
The cyclin pathway may confer resistance to standard treatments but also offer novel therapeutic opportunities in prostate cancer. Herein, we analyzed prostate cancer samples (majority metastatic) using comprehensive genomic profiling performed by next-generation sequencing (315 genes, >500x coverage) for alterations in activating and sensitizing cyclin genes (CDK4 amplification, CDK6 amplification, CCND1, CCND2, CCND3, CDKN2B [loss], CDKN2A [loss], SMARCB1), androgen receptor (AR) gene, and coalterations in genes leading to cyclin inhibitor therapeutic resistance (RB1 and CCNE1). Overall, cyclin sensitizing pathway genomic abnormalities were found in 9.7% of the 5,356 tumors. Frequent alterations included CCND1 amplification (4.2%) and CDKN2A and B loss (2.4% each). Alterations in possible resistance genes, RB1 and CCNE1, were detected in 9.7% (up to 54.6% in neuroendocrine) and 1.2% of cases, respectively, whereas AR alterations were seen in 20.9% of tumors (similar to 27.3% in anaplastic). Cyclin sensitizing alterations were also more frequently associated with concomitant AR alterations.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available